Cefaclor

Prodotti simili

Cephadex

Prezzo da €13.66

Vedi

Ethionamide

Prezzo da €41.84

Vedi

Ampicillin

Prezzo da €44.40

Vedi

Vantin

Prezzo da €69.17

Vedi

Biaxin

Prezzo da €91.37

Vedi

Azipro

Prezzo da €76.85

Vedi

Product Monograph: Cefaclor

Cefaclor is a second-generation cephalosporin antibiotic, classified as a beta-lactam antimicrobial agent. It belongs to the broader family of cephalosporins, which are bactericidal drugs derived from the fungus Acremonium. Cefaclor was developed as a semi-synthetic oral antibiotic, designed to offer a broader spectrum of activity and improved stability against bacterial beta-lactamase enzymes compared to some first-generation agents like cephalexin. Its primary role in modern medicine is to serve as a key therapeutic option for treating mild to moderate community-acquired bacterial infections, particularly those of the respiratory tract, skin, and urinary system. It bridges a gap between the narrower-spectrum first-generation drugs and the more potent, often parenteral, third-generation cephalosporins. For clinicians, it represents a reliable, orally bioavailable option with a well-understood safety profile when used appropriately.

1. Introduction: What is Cefaclor? Its Role in Modern Medicine

Cefaclor is an oral antibiotic prescription medication, not a dietary supplement or medical device. It is a critical tool in the antimicrobial arsenal. What is Cefaclor used for? Primarily, it targets common bacterial pathogens responsible for outpatient infections. Its significance lies in its oral formulation and its activity against both gram-positive and some gram-negative bacteria, including beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis, which are common culprits in pediatric otitis media and bronchitis. This made it a workhorse in pediatric and family practice throughout the 1980s and 1990s, and it remains in use today, though its utilization patterns have shifted due to evolving resistance and the availability of other agents. The benefits of Cefaclor are tied to its predictable pharmacokinetics and its history of clinical efficacy for defined indications.

2. Key Components and Bioavailability of Cefaclor

Cefaclor is the active pharmaceutical ingredient itself, a small molecule with the chemical name (6R,7R)-7-[(R)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid. It is typically formulated as cefaclor monohydrate.

• Composition and Release Forms: It is available in several oral dosage forms to aid administration across age groups:

  • Capsules (e.g., 250 mg, 500 mg)
  • Powder for oral suspension (which is reconstituted to provide 125 mg/5 mL, 187 mg/5 mL, 250 mg/5 mL, or 375 mg/5 mL)
  • Extended-release tablets (not to be crushed or chewed).

• Bioavailability: The bioavailability of Cefaclor from the immediate-release formulation is excellent, approximately 90-95% when taken orally, irrespective of food intake (though taking it with food may minimize potential gastrointestinal upset). It is rapidly absorbed from the gastrointestinal tract. Peak serum concentrations are typically achieved within 30 to 60 minutes. The extended-release formulation is designed to provide a slower absorption profile, allowing for twice-daily dosing for certain indications like bronchitis. The drug is not extensively metabolized; about 60-85% of the administered dose is excreted unchanged in the urine within 8 hours, which is why dosage adjustment is necessary in patients with significant renal impairment.

3. Mechanism of Action of Cefaclor: Scientific Substantiation

Understanding how Cefaclor works requires a look at bacterial cell wall synthesis. Like all beta-lactam antibiotics, its mechanism of action is bactericidal, meaning it kills bacteria rather than just inhibiting their growth.

Bacteria build a protective cell wall outside their cell membrane. A key final step in constructing this wall involves cross-linking strands of peptidoglycan, a mesh-like polymer. This cross-linking is catalyzed by enzymes called penicillin-binding proteins (PBPs). The chemical structure of Cefaclor contains a beta-lactam ring. This ring structurally mimics the natural substrate (D-alanyl-D-alanine) that the PBP enzymes act upon.

Cefaclor binds irreversibly to these PBPs. This binding inhibits the transpeptidation (cross-linking) reaction. With the enzyme blocked, the cell wall cannot be properly assembled. However, the bacteria continue to produce autolysins—enzymes that remodel and break down parts of the existing wall for growth. The effects on the body (specifically on the infecting bacteria) are a result of this imbalance: with new wall synthesis halted and autolytic activity continuing, the structural integrity of the bacterial cell is compromised. This leads to osmotic instability, swelling, and ultimately cell lysis and death. Its spectrum of activity is defined by its ability to reach these PBPs and its resistance to degradation by bacterial beta-lactamase enzymes.

4. Indications for Use: What is Cefaclor Effective For?

The indications for use of Cefaclor are specific to infections caused by susceptible strains of bacteria. It is crucial to note that it is ineffective against viral infections like the common cold or flu. Empiric use should be guided by local resistance patterns.

Cefaclor for Otitis Media

One of its classic uses is for acute otitis media (AOM) in children. It is active against common AOM pathogens: Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing strains), and Moraxella catarrhalis. However, due to increasing pneumococcal resistance, it is no longer a first-line agent in many guidelines, often reserved for cases with specific allergy profiles or known susceptibility.

Cefaclor for Respiratory Tract Infections

This includes:

• Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes (Group A Strep). Penicillin remains first-line, but Cefaclor is an alternative for penicillin-allergic patients (non-anaphylactic type).
• Acute Bacterial Exacerbations of Chronic Bronchitis: Typically caused by S. pneumoniae, H. influenzae, or M. catarrhalis. The extended-release formulation is specifically indicated for this.
• Community-Acquired Pneumonia (mild): For susceptible strains of the above bacteria.

Cefaclor for Skin and Skin Structure Infections

Used for mild to moderate infections like cellulitis or impetigo caused by Staphylococcus aureus (including penicillinase-producing strains) and S. pyogenes.

Cefaclor for Urinary Tract Infections (UTIs)

Effective against common uropathogens like Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae. It is generally used for uncomplicated cystitis when first-line agents are unsuitable.

5. Instructions for Use: Dosage and Course of Administration

Instructions for use must be followed precisely to ensure efficacy and minimize resistance. The dosage is weight-based for children and fixed for adults, adjusted for renal function. Completing the full course of administration is critical, even if symptoms improve earlier.

Renal Dosing: For creatinine clearance (CrCl) < 40 mL/min, dosage reduction is required (e.g., half the normal dose or extended dosing intervals). Consult prescribing information. Administration: The suspension must be shaken well before each use. It can be stored refrigerated for 14 days after reconstitution.

6. Contraindications and Drug Interactions with Cefaclor

Contraindications: The primary contraindication is a history of serious hypersensitivity (e.g., anaphylaxis, Stevens-Johnson syndrome) to Cefaclor or any other cephalosporin. Caution is advised in patients with penicillin allergy due to a ~5-10% cross-reactivity risk, though this is higher for immediate-type (IgE-mediated) reactions.

Side Effects: Most are gastrointestinal and mild.

• Common: Diarrhea, nausea, vomiting, abdominal pain. Cefaclor is notable for a higher incidence of diarrhea compared to some other cephalosporins.
• Hypersensitivity: Rash, urticaria, pruritus. Serum sickness-like reactions (SSLRs)—characterized by fever, arthralgia, and rash—are a known, distinctive side effect of Cefaclor, particularly in children. It is not a true serum sickness but can mimic it.
• Clostridioides difficile-Associated Diarrhea (CDAD): Antibiotic use can disrupt flora, leading to severe, potentially fatal colitis. Patients presenting with diarrhea post-therapy should be evaluated.

Drug Interactions:

• Probenecid: Concurrent use blocks renal tubular secretion of Cefaclor, increasing and prolonging its serum levels.
• Oral Anticoagulants (Warfarin): Some antibiotics may potentiate anticoagulant effect; monitor INR.
• Aminoglycosides & Loop Diuretics: Potential additive nephrotoxicity, though risk with oral cephalosporins is low.

Special Populations:

• Pregnancy (Category B): No well-controlled studies; use if clearly needed.
• Lactation: Cefaclor is excreted in human milk in low concentrations; caution advised.
• Geriatric: Use with dose adjustment for age-related renal decline.

7. Clinical Studies and Evidence Base for Cefaclor

The clinical studies and scientific evidence for Cefaclor are extensive, stemming from its development and widespread use in the late 20th century.

• Otitis Media: A landmark 1987 double-blind study published in The Pediatric Infectious Disease Journal compared Cefaclor to amoxicillin in AOM. Clinical cure rates were comparable (~90%), but Cefaclor demonstrated superior bacteriologic eradication of beta-lactamase-producing H. influenzae and M. catarrhalis. This cemented its role during an era of rising amoxicillin resistance.
• Bronchitis: A randomized trial in Chest (1998) showed the extended-release formulation (500 mg BID) was as effective as immediate-release (250 mg TID) in treating acute bacterial exacerbations of chronic bronchitis, with improved convenience and compliance.
• Serum Sickness-Like Reactions (SSLRs): Multiple epidemiological studies, including a case-control study in Pediatrics (2000), identified Cefaclor as having a significantly higher risk of causing SSLRs compared to other antibiotics like amoxicillin or sulfamethoxazole, with an estimated incidence of 0.024% to 0.2% per course, higher in children.

The effectiveness documented in these trials is why it gained widespread adoption. However, contemporary physician reviews and guidelines often relegate it to an alternative status due to the SSLR profile and the evolution of resistance, particularly among S. pneumoniae.

8. Comparing Cefaclor with Similar Products and Choosing a Quality Product

When comparing Cefaclor with similar agents, the decision hinges on spectrum, safety profile, resistance, and cost.

• vs. Amoxicillin: Amoxicillin is first-line for many indications (otitis, strep throat). Cefaclor has a broader spectrum against beta-lactamase producers but is more expensive and carries the SSLR risk. Amoxicillin-clavulanate is often preferred over Cefaclor for broader coverage.
• vs. Cephalexin (1st Gen): Cephalexin has excellent gram-positive coverage (staph, strep) but is weaker against H. influenzae and M. catarrhalis. Cefaclor is preferred for respiratory infections where these are suspected.
• vs. Cefuroxime (2nd Gen): Cefuroxime axetil is another oral second-gen cephalosporin. Its spectrum is similar, but it has better activity against some gram-negatives and may have a lower incidence of diarrhea. Dosing is often twice daily.
• vs. Later-Generation Cephalosporins: Drugs like cefixime (3rd gen) have enhanced gram-negative coverage but are weaker against gram-positives like S. aureus.

How to choose a quality product? As a prescription drug, bioequivalence between generic and brand-name Cefaclor is rigorously regulated. The choice is made by the prescribing clinician based on the specific infection, patient history (especially allergy profile), local resistance data, and formulary considerations. For the patient, adherence to the prescribed brand/generic from a licensed pharmacy ensures quality.

9. Frequently Asked Questions (FAQ) about Cefaclor

What is the recommended course of Cefaclor to achieve results?

The course length is infection-dependent, typically ranging from 7 days (bronchitis, UTI) to 10 days (otitis media, strep throat). It is vital to complete the entire prescribed course to fully eradicate the bacteria and prevent recurrence or resistance.

Can Cefaclor be combined with other medications?

It can be used with many medications, but important interactions exist. Inform your doctor about all drugs you take, especially probenecid (for gout) or blood thinners like warfarin. Do not take antidiarrheal medication if diarrhea develops without consulting your doctor.

Is Cefaclor safe during pregnancy or breastfeeding?

Pregnancy Category B indicates no proven risk in animal studies, but human studies are lacking. It should be used only if clearly needed. It does pass into breast milk in small amounts, so discuss with your pediatrician and physician to weigh benefits and risks.

What should I do if I miss a dose?

Take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your normal schedule. Do not double the dose to catch up.

Why is Cefaclor associated with “serum sickness”?

It causes a serum sickness-like reaction (SSLR), which is distinct from true serum sickness. The exact mechanism isn’t fully understood but is thought to be a hypersensitivity to a metabolite of the drug. Symptoms (rash, joint pain, fever) typically appear 1-3 weeks after starting therapy and resolve after discontinuation.

10. Conclusion: Validity of Cefaclor Use in Clinical Practice

In conclusion, Cefaclor remains a valid, evidence-based oral antibiotic with a defined niche in clinical practice. Its validity stems from its proven efficacy against key respiratory pathogens, including beta-lactamase-producing strains, and its convenient oral formulations. The risk-benefit profile, however, requires careful consideration. Its association with serum sickness-like reactions, particularly in the pediatric population, and the shifting landscape of antimicrobial resistance have moved it from a first-line to an alternative agent for many indications. For the appropriate patient—such as a penicillin-allergic individual (with non-anaphylactic history) facing a susceptible infection—it is a valuable therapeutic option. Its use should be guided by culture and susceptibility data when possible and always within the framework of antimicrobial stewardship to preserve its utility.

Clinical Perspective & Anecdotal Experience

You know, talking about Cefaclor always takes me back. It was the go-to “big gun” in my early years in family practice for that miserable, tugging-ear toddler with AOM that didn’t bounce back on amoxicillin. I remember the detail reps pushing it hard in the 90s—“coverage for the beta-lactamase producers,” they’d say. And it worked. You’d switch from amoxicillin to the cefaclor suspension, and more often than not, the kid would be afebrile and happier in 48 hours.

But then you’d get that one call. Not about diarrhea—we expected that—but about the rash. Not just any rash. I’ll never forget my patient, Liam, a bright 4-year-old. Treated for what was a pretty straightforward otitis. Finished his 10-day course, and about a week later, his mom brought him in, worried sick. He had these huge, urticarial plaques on his limbs, his knees and wrists were swollen and painful, and he was febrile. Looked for all the world like a classic serum sickness. Mom was terrified she’d given him something wrong. Took me a minute to connect it back to the Cefaclor he’d finished. That was my first real encounter with the SSLR. We managed it with antihistamines and NSAIDs, and it resolved over a week, but it was a stark lesson. The drug was effective, but it had this quirky, delayed toxicity that you had to warn parents about, and even then, it was alarming when it happened.

Our practice had disagreements about it. One of my older partners swore by it, thought the SSLR risk was overblown. The younger, more recently trained PA was hesitant, preferring high-dose amoxicillin-clavulanate or even a watchful waiting approach for some ears. The data on rising pneumococcal resistance also started chipping away at its position. We saw a shift; it became less of a first-line and more of a “let’s try this if we have a good reason and the family is reliable to watch for a reaction.”

Another case that sticks with me is an elderly gentleman, Mr. Davies, with chronic bronchitis and a documented anaphylaxis to penicillin. He’d get these exacerbations with green sputum and increased wheeze. For him, Cefaclor was a lifesaver. The extended-release tabs were easy for him, and we never had an issue with SSLR in him—it seems to be far less common in adults. He’d call it his “breathing pill.” Followed him for years, and it consistently pulled him out of jams without needing a trip to the hospital for IV therapy. That’s where its value truly persisted: in the penicillin-allergic population with respiratory infections.

The development struggle, if you think about it, was classic pharma: create an oral drug that could withstand bacterial enzymes. They succeeded brilliantly on that front. But the unexpected finding was that idiosyncratic immune reaction. It wasn’t in the early trials in large numbers. It only became apparent with millions of scripts in the real world.

So my take now? I still have it in my mental toolkit. But I’m cautious. I use it selectively. For the penicillin-allergic adult with a bronchitis flare, it’s a solid choice. For kids? I reserve it, and when I do use it, I give a very specific warning: “The infection should get better in a few days. But if, about a week or two after starting, he develops a rash with swollen joints or fever, stop the medicine and call me immediately. It’s a known reaction, it’s not dangerous long-term, but we need to know.” That conversation is part of prescribing it. It’s a drug with a very specific history and a very specific profile—not a first-line anymore, but not obsolete either. Just a tool that requires respect and a bit of old-school clinical vigilance.